Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Rilpivirine (Edurant®) is recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive patients from 12 years old to < 18 years old with a viral load ≤ 100,000 HIV-1 RNA copies/ml. |
|||
|
|||
Medicine details |
|||
| Medicine name | rilpivirine (Edurant®) | ||
| Formulation | 25 mg film-coated tablet | ||
| Reference number | 2936 | ||
| Indication | Treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naive patients from 12 years old to < 18 years old with a viral load ≤ 100,000 HIV-1 RNA copies/ml |
||
| Company | Janssen-Cilag Ltd | ||
| BNF chapter | Infections | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 2616 | ||
| NMG meeting date | 20/07/2016 | ||
| AWMSG meeting date | 21/09/2016 | ||
| Ratification by Welsh Government | 04/10/2016 | ||
| Date of issue | 05/10/2016 | ||
| Date of last review | July 2020 | ||